Mean change in the hemoglobin level from baseline
Regarding ΔHb, this network meta-analysis included 20 trials involving 6
HIF-PHIs (Supplementary Figure S16). Substantial heterogeneity
(I2=74.6%) led to choosing random-effects models in the following
analyses. A significant increase
was found in efficacy between Roxadustat and ESAs (MD:0.19 g/dL,
95%CI:0.07-0.30, p<0.01), and no statistic differences were
found with Enarodustat, Daprodustat, Desidustat, Vadadustat, and
Molidustat. Since the network structure for DD CKD patients contains no
loop, the full design-by-treatment interaction random-effects model is
not applied. Moreover, the net-rankings were Roxadustat (0.88),
Desidustat (0.72), Enarodustat (0.60), Daprodustat (0.56), ESAs (0.46),
Vadadustat (0.23), and Molidustat (0.05).